Showing results (41-50 of 55) with videos related to

Sort By:
Pageof 6
JCO Global Oncology|June 6, 2024
Implementation of Universal Pan-Cancer Germline Genetic Testing in an Arab Population: The Jordanian Exploratory Cancer Genetics StudyHikmat Abdel-Razeq, Baha' Sharaf, Hira Bani Hani, et al.
Journal of the American Academy of Dermatology|March 21, 2024
Germline cancer susceptibility in individuals with melanomaPauline Funchain, Ying Ni, Brandie Heald, et al.
Prostate Cancer and Prostatic Diseases|September 22, 2025
Using patient-reported outcomes from the PROCLAIM trial to assess the impact of universal germline genetic testing for prostate cancer patientsNeal D Shore, Christopher M Pieczonka, Sean Heron, et al.
NPJ Genomic Medicine|November 24, 2024
Germline sequence variation in cancer genes in Rwandan breast and prostate cancer casesAchille Vc Manirakiza, Shakuntala Baichoo, Annette Uwineza, et al.
The Journal of Urology|August 9, 2024
Clinician-Reported Management Recommendations in Response to Universal Germline Genetic Testing in Patients With Prostate CancerNeal Shore, Christopher Pieczonka, Sean Heron, et al.
European Urology Oncology|August 13, 2023
Efficacy of National Comprehensive Cancer Network Guidelines in Identifying Pathogenic Germline Variants Among Unselected Patients with Prostate Cancer: The PROCLAIM TrialNeal Shore, Mukaram Gazi, Christopher Pieczonka, et al.
JAMA Network Open|September 22, 2022
Clinical Utility of Universal Germline Genetic Testing for Patients With Breast CancerPat W Whitworth, Peter D Beitsch, Rakesh Patel, et al.
Cancers|May 28, 2022
Clinical Impact of Pathogenic Variants in DNA Damage Repair Genes beyond BRCA1 and BRCA2 in Breast and Ovarian Cancer PatientsWhitney Espinel, Marjan Champine, Heather Hampel, et al.
JCO Oncology Practice|December 19, 2024
Implementation of Universal Germline Genetic Testing Into Standard of Care for Patients With Prostate Cancer: The Time Is NowNeal Shore, Sarah M Nielsen, Edward D Esplin, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|December 15, 2021
Risks of breast and ovarian cancer for women harboring pathogenic missense variants in BRCA1 and BRCA2 compared with those harboring protein truncating variantsHongyan Li, Christoph Engel, Miguel de la Hoya, et al.
Pageof 6